AstraZeneca Q2 Profit Rises 2% as Cancer Drug Sales Beat Expectations
AstraZeneca reported stronger-than-expected second-quarter earnings on Monday, with net profit rising 2% year-on-year as robust demand for its cancer medicines helped offset recent challenges in its drug development pipeline.
The Anglo-Swedish pharmaceutical company posted a net profit of $2.51 billion for the three months ended June 30, compared with the same period last year. Revenue increased 5% at constant exchange rates to $15.38 billion, supported by continued growth across its oncology and rare disease portfolios.
The results exceeded market expectations, prompting AstraZeneca to reaffirm its full-year 2026 financial outlook.
Core earnings per share rose 18% at constant exchange rates to $2.63, surpassing analysts' consensus estimate of $2.48.
Shares of the Cambridge-based drugmaker gained around 1.4% in early European trading following the earnings announcement.
Chief Executive Pascal Soriot said the company remains on course to achieve its long-term objective of generating $80 billion in annual revenue by 2030.
"We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months," Soriot said.
The earnings report comes weeks after AstraZeneca experienced a setback when its experimental treatment Wainua failed to meet key objectives in a late-stage clinical trial, triggering a decline in the company's share price earlier this month.
Despite that disappointment, the company's oncology portfolio continued to deliver strong performance, reinforcing AstraZeneca's position as one of the world's leading cancer drug manufacturers.
Beyond oncology, AstraZeneca is expanding its presence in the fast-growing obesity treatment market.
In June, the company reported positive mid-stage trial results for its experimental oral weight-loss medicine elecoglipron. Patients receiving the highest dose lost an average of 10.5% of their body weight after 26 weeks, with weight reduction increasing to 11.8% after 36 weeks.
If future clinical studies confirm those findings, AstraZeneca could become a significant competitor in the global obesity treatment market, currently led by Novo Nordisk and Eli Lilly.
The latest quarterly results underline the resilience of AstraZeneca's core pharmaceutical business despite ongoing research risks and intensifying competition across the global healthcare sector.
More News:-
Recent Comments:
No comments yet.